at Could Impact the ledicine Market

enhance the healing of wounds while reducing scarring.

And if given the choice would you buy Neosporin or Neosporin with stem cell based technology?

According to Market
Research Reports, the global
regenerative medicine market,
which includes cosmeceuticals
& pharmaceuticals, is currently
a \$16.4 billion global market
that is expected to grow
to \$67.6 billion by 2020, a
compounded annual growth
rate of 23.2%.

NuGene's new acquisition when combined with stem cell media could have many applications in regenerative wound treatment and healing but based on **NUGN's** SEC filings I believe one of their targets will be the burn market.

A Burn Cream That Could Fire Up the Market

Burn injuries are a global epidemic of staggering proportions. The annual number of burn victims is so huge that in the U.S. alone there are an estimated 2.1 million victims each year, a market that exceeds \$2.5 billion annually.

What's amazing, however, is that the bulk of the \$2.5 billion in revenues come from old-fashion burn treatments mostly consisting of anti-infectives ... treatments that while anti-biotic don't promote skin regrowth.

Enter NuGene's stem cell derived technology where medical studies have shown that growth factors stimulate growth, as well as regenerate and accelerate the repair of skin.

NuGene's OTC monographed FDA-approved drug, when combined with stem cell media, if proven to promote skin regrowth, could have big potential! Biotech breakthroughs have gigantic upside:

- Early investors in Celgene could have cashed out with a 57,119% gain. That would have turned \$100 into more than \$50,000... and \$1,000 into more that \$500,000.
- There would be a similar outcome for Biogen Idec, too. Ground-floor investors could have walked away with a 34,239% gain.
- Cellular Biomedicine went public at \$5 in March 2014. It's already up 680%.

Analyst Projection

June 2016 Target

\$25.08

Growth Factor: Distribution base grew 200% in Q4

With Kathy Ireland on board shares could soar FAST!

December Target \$12.54

September Target \$6.27

NuGene Light & Bright Gel Reduces \$

Stem cell technology reverses appearance of aging by b melanin, resulting in lighter & younger skir

he problem: Few things make us look older than brown spots on the skin... known by names such as liver spots, freckles, hyperpigmentation, melasma and skin blotches... these sudden imperfections can be a more outward sign of aging than wrinkles are.

These brown spots typically occur in people older than 40 and are one of the most common reasons for a trip to the dermatologist's office.

As we age, the skin renewal process slows down and skin loses its ability to regenerate. Babies can regenerate new skin cells in as little as 14 days. This same repair process takes up to 37 days in a 50 year old. Stem cells make this regeneration process possible.

The market: Skin lightening products represent one of the most rapidly growing segments in a global market that is projected to reach \$19.8 billion by 2018.

Recent demographics indicate that 46% of Americans are age 40 and above - that's roughly 147 million people in the U.S. that could have

some form of spotting or pigment imperfection.

The status-quo: Many skin lightening products in the U.S. contain hydroquinone, a skin bleaching agent that has been banned in dozens of countries across Europe, Australia, and parts of Asia and Africa because of evidence indicating that hydroquinone may cause cancer.

Why is it still prescribed in the USA when it has largely been abandoned elsewhere due to reported adverse effects and detrimental health warnings?

Our Skin as We Age

In our 20s FREE RADICALS ENVIRONMENTAL

Due to constant exposure to the sun and a hectic lifestyle we begin to deal with damage which leads to the premature development of fine lines & wrinkles.

In our 30s

DULLNESS DISCOLORATION

Skin starts to take twice as long to regenerate leading to a dull complexion and uneven skintone. Collagen and elastin degradation leads to the first apearance of deep wrinkles.

REDNESS DRYNESS

Thinning skin leads to poor circulation causing redness and sensitivity. The skin starts to become more susceptible to photo aging leading to the appearance of age spots.

In our 50s+

DECREASE IN SKIN BARRIER DEGRADATION

Decrease in surface immunity impairs the skins ability to protect itself. The natural skin barrier degrades, leading to poor moisture retention and excessive dryness.

igns of Age-Spots & Sun Damage

reaking down

The solution: NuGene's bio-active ingredients can help improve the look and feel of aging skin by revving up the skin regeneration process.

NuGene's products contain proteins derived from human stem cells called growth factors and cytokines, providing the body's own stem cells with more 'fuel' to improve the skin's appearance.

NuGene's potent Light & Bright Gel works to break down excess melanin, reducing the look of dark spots and excess pigmentation

skin as we age



without any of the harsh ingredients typically found in brightening products.

The opportunity: It is easy to see how NuGene and Kathy Ireland could impact the multibillion dollar hyperpigmentation industry.

How suddenly, and with little

warning to its competitors, millions of dollars could quickly flow to NuGene International (NUGN).


Imagine what could happen if consumers become educated or the USA and Canada follow Europe's lead and ban the cancer causing hydroquinone.

Peak Levels

Light & Bright Gel



This potent product works to break down excess melanin in the skin without any of the harsh ingredients typically found in brightening products. Its exclusive blend of ingredients is clinically proven to act faster and better than the leading prescription skin-brightening ingredients – yet it's gentle enough to use every day. And, in addition to quickly reducing the look of dark spots and excess pigmentation, it works to increase overall radiance, restoring a youthful glow.



PEOPLE LOVE THEIR Untitled - Notepad File Edit Format View Help Censored photos of ugly people 20 | MicroCap MarketPlace



Advertisement

Continued from page 12 and consumers across the globe could go crazy for NUGN.

NuGene (NUGN) could be poised to jump from doctors' shelves to retail stores and worldwide distribution with Kathy Ireland's recently announced involvement!

Could One of The World's Most Influential **Brands Use Their** Relationships to Launch NuGene (NUGN) in **Major Retailers?**

NuGene's anti-aging product line is only available through doctors, medical spas or online at www.dermalstore.com

But, Kathy Ireland Worldwide's brand partnership with NUGN could be a game changer.

Could Kathy Ireland use her company's global distribution system to bring NuGene to bigbox retail stores such as Target, Macy's and Nordstrom?

If so that means NUGN's revenue potential... profit potential... share price potential... could be off the charts.

Smart investors will stay ahead of this fast breaking opportunity and make a move while it's still early as this could be the microcap mega-opportunity!

Growing fast in a hot sector!

Looking at the cosmetics industry and a sampling of cosmetics competitors, we see

Continued on page 22

3 41 Untitled - Notepad File Edit Format View Help

Picture of Kathy Ireland blocked due to DMCA takedown request

Continued from page 21

that the sector companies below are valued at an average price to earnings multiple of 37.29!

NuGene reported in February 2015, that with the stroke of a pen it increased distribution 200%, adding 50 new locations in November and December 2014 through a mix of doctors and medical spas bringing its total number of locations to 75.

While this may not sound like a ton, NuGene also reported it had booked \$320,000 in product orders to these locations in December.

That's an average of \$4,267 per location for just a one month period!

We can only imagine how large distributors with thousands of locations could grow sales when Kathy Ireland Worldwide

uses its global influence for NuGene.

What happens to the stock price if Kathy Ireland's brand helps launch NuGene from doctors offices into high traffic big box retailers such as:

- Nordstroms 291 stores
- Macys 840 stores
- Target 1,795 stores

NUGN has 39,197,400 common and 1,917,720 series A preferred shares outstanding. For the purposes of being conservative in our calculations we will use the aggregated total capitalization of 41,115,120 shares outstanding.

Assuming **NUGN** is able to achieve an 18% profit margin,

Name	Ticker	P/E
Estee Lauder	EL	28.54
Inter Parfums	IPAR	39.79
Ulta Salon, Cosmetics	ULTA	37.80
Revion	REV	43.03
Average		37.29

P/E: Calculated by Yahoo Finance 3/9/15





a price to earnings multiple of 37.29 and that the company averages \$4,267 in sales per location per month, NUGN could achieve the following:

If NUGN trades at an average P/E of 37.29, achieves a profit margin of 18% and is sold in 3,000 locations that produce purchase orders of \$4,267 per month, its shares could be valued at \$25.08

Assumed Locations	Projected Revenue	Projected Net Income	Projected Price
750	\$38,400,000	\$6,912,000	\$6.27
1,500	\$76,800,000	\$13,824,000	\$12.54
3,000	\$153,600,000	\$27,648,000	\$25.08
5,000	\$256,000,000	\$46,080,000	\$41.79

Assumes: A profit margin of 18%; 41,115,120 shares outstanding; a P/E of 37.29; \$4,267 in revenue per location per month.

Bear in mind that this simple projection DOESN'T calculate for the grand slam potential of:

- Big box retail distribution
- An FDA-approved skin protectant
- The hair regrowth market potential



Nugene As Featured on www.DermalStore.com



Continued from page 23

OPPORTUNITIES LIKE NUGN ARE RARE!

Kathy Ireland is a brand that is not only trusted & respected on Wall Street but also by women across the country... Nugene's core sales demographic.

Right now, NuGene is still an undiscovered stock. The news about Kathy Ireland has yet to reach Wall Street because **NUGN** is new to the stock market.

The fact that she is the face of NuGene cannot remain a secret for long... when word gets out can investors risk being on the sideline?

The full market potential for NuGene's anti-aging product lines could cause NuGene (NUGN) to continue to soar for years to come!



And the cosmetics sector is hot:

- Like the retail cosmetic firm ULTA whose stock is up 3,329% since March 2009.
- Revlon's stock is up 1,253% since March 2009.
- Estee Lauder's stock is up 737% since March 2009.
- · Could NUGN be next?

With so much potential upside, how long will NUGN

trade at its current levels?

Visit www.nugene.com, read the SEC filings, and call your broker to find out if **NUGN** is a suitable investment for your portfolio.

If he gives you the green light and you profit from this report please remember to subscribe to MicroCap MarketPlace for one year at our special report pricing to receive these investment insights in the future. ■

INDUSTRY NEWS ALERT

Actavis agrees to buy Botox-maker Allergan for \$66 billion

- November 17, 2014

Deal sidelines a hostile takeover offer by Valeant Pharmaceuticals.

Actavis has agreed to pay about \$66 billion to buy Botox-maker Allergan in a cash-and-stock deal that likely sidelined a rival offer by Valeant Pharmaceuticals. Could NuGene become the next big winner?

Mike... I want to subscribe to MicroCap MarketPlace. I understand that my RISK-FREE subscription comes with a 90-day, 100% money-back guarantee. Sign me up for a no-risk subscription today.

A GREAT DEAL — One-Year Subscription for \$389 \$97 - Sign me up for a full year of the MicroCap MarketPlace at a discount of 75% off the regular rate. That's a \$97 deal that could put thousands of dollars in my pocket.

For a one-year subscription log on at microcapmarketplace.com

My Personal Guarantee - NO RISK Try MicroCap MarketPlace ABSOLUTELY RISK FREE for 90 days

If you are not completely satisfied for any reason in the first 90 days, simply let me know and I'll issue you a full 100% refund of your subscription. After that, I'll refund the balance left on your subscription. Everything you have received up to that point is yours to keep with my compliments.

Here's the full deal:

- You will receive a 100% money-back subscription refund if you cancel within the first 90 days of your initial term. Anytime after that, I'll refund the balance of months remaining in the term of your subscription, should you become disenchanted for any reason. And, you still get to keep everything you've received up to that point as our thanks for joining my investment newsletter group.
- To avoid a lapse in service, your subscription will be automatically renewed at the end of the term and we'll lock in your current discounted price.
- Privacy Guarantee you can rest assured that we will not sell your name or email address to any third party.
- There're not a lot of frills and freebies to this offer (do you really care about those "special reports" that are yesterday's news?); it's just good, solid research on micro and small cap stocks that can potentially make you up to 10 times your money.

POTENTIAL TAX SAVINGS: Your subscription to MicroCap MarketPlace may be tax deductible. Don't forget to ask your accountant!

NuGene's team is comprised of highly res

Ali Kharazmi, JD, MBA, CEO & Director

Former Vice President of Business Development for Republic Health, the third largest for profit hospital group, went on to co-found Medical Information Networks, one of the first medical technology companies to provide electronic prescription services to physicians. He went on to found the Genetic Institute of Anti-Aging & Center for Weight Management and Plastic Surgery, as well as OrthoRegeneration, a sport and orthopedic regeneration practice specializing in PRP and adult stem cell based regenerative medicine.

M. Kharazmi, MD, Chairman & Director

Obtained his MD from University of California, Irvine in 1992 and completed his Chief Residency at St. Mary Medical Center/UCLA in 1996. Dr. Kharazmi joined UCR as HS Assistant Clinical Professor and became the Medical Director of UCRHealth. He is also the Medical Director for Advanced Surgical Partners and Founder of the Genetic Institute of Anti-Aging.

Sanjay Dhar, PhD, Executive Director of Stem Cell Research

Founding Director of Center for Tissue Engineering & Regenerative Medicine at Aesthetic & Plastic Surgery Institute, University of California, Irvine. There he started programs focused on peripheral nerve regeneration, and bone & cartilage regeneration using growth factors and stem cells. Recognized as one of the world's most outstanding scientists and a leader in adipose derived stem cells research, he was a part of the team which demonstrated that adipose derived stem cells can be differentiated into bone and cartilage for the treatment of defects. He also developed a model of delivering nerve growth factor to the severely injured peripheral nerves for recovery & regeneration. Dr. Dhar has published numerous papers in peer reviewed journals and is the recipient of numerous awards for his pioneering work.

Fady Elias, MD Director of Professional Business Development

Dr. Elias practices orthopedic sports medicine and specializes in orthobiologics, the use of stem cells in treating orthopedic injuries and disease. He has treated professional athletes as well as patients from all over the world. He was asked to join NuGene two years ago as VP of business development because of his experience with autologous stem cells in his own clinical practice.

Shahrokh Zekavati, PhD, Executive Director of Manufacturing

Having 30 years of Cosmetic and Pharmaceutical Industry experience, he earned his Doctorate of Engineering and Master of Science in Physical Organic Chemistry from the University of Science and Technology at Languedoc – Montpellier (France) and Engineer in Training (EIT) from CA, USA. He also earned another Master of Science and Bachelor of Science in Chemical Engineering from Tehran University (Iran).

Mitchell P. Goldman, MD, Advisory Board

A world-renowned, double-board certified dermatologist and cosmetic surgeon, recognized by the American Board of Dermatology and the American Board of Cosmetic Surgery. A graduate of Boston University (Summa Cum Laude and Phi Beta Kappa) and Stanford University Medical School, Dr. Goldman is recognized for pioneering research on multiple laser techniques, skin rejuvenation, liposculpture and vein therapy. He is also the co-founder of SkinMedica. He is a volunteer clinical professor of Dermatology at the University of California, San Diego, Honorary Professor of Dermatology for the Chinese Academy of Medical Sciences, and the founder and Medical Director of Cosmetic Laser Dermatology. He is considered a leading expert in laser surgery and resurfacing, liposculpture, sclerotherapy, laser closure

ected MDs & PhDs:

of varicose veins, dermal filling treatments, Botox®/ Dysport®/ Xeomin® therapy, photorejuvenation, and photodynamic therapy. He is the Director of the American Society for Dermatologic Surgery Fellowship Program and has practice/hospital affiliations with Scripps Memorial Hospital in La Jolla, California.

Vivian Bucay, MD, Advisory Board

Dr. Bucay has been featured as a skin expert in publications including Allure, Cosmetic Surgery Times, Elle, More, Shape, Prevention, and Good Housekeeping. She has been featured as a keynote speaker across the globe on topics ranging from innovations in facial aesthetics to neuromodulators to cancer survival. She is recognized nationally for her expertise in minimally invasive facial rejuvenation through the combined use of neuromodulators, injectable dermal fillers, and skin resurfacing. Considered to be one of the pre-eminent dermatologists in the country.

Mark Kobayashi, MD, Advisory Board


Specializes in aesthetic surgery that includes all

areas of plastic surgery including reconstructive and microvascular surgery. He is evaluating various techniques to improve peripheral nerve repair and his research focus is on enhancing nerve regeneration. He is a widely published author of medical journal articles and is Associate Clinical Professor of Surgery at the Aesthetic & Plastic Surgery Institute of the University of California, Irvine.

Dendy Engelman, MD, Advisory Board

A board certified dermatologic surgeon and an associate at Manhattan Dermatology & Cosmetic Surgery, Dr. Engelman attended Wofford College and was inducted into Phi Beta Kappa, graduating summa cum laude with honors. Dr. Engelman earned the Presidential Scholar award and was also awarded the Humanism in Medicine Scholarship. She has extensive training and experience in cosmetic dermatology including neurotoxins, injectable fillers, and chemical peels. Most recently, Dr. Engelman was appointed Director of Dermatologic Surgery at New York Medical College where she oversees the training of future Mohs surgeons and dermatologists.

Disclaimer: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND IN THIS REPORT. This publication is distributed free of charge and does not purpor to provide an analysis of a company's financial position. The information contained herein has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company, including NuGene International, Inc. (NUGN). NuGene International, Inc.'s (NUGN) financial position and all other information regarding NuGene International, Inc. (NUGN) should be verified with the company. An individual should not invest in the securities of NuGN) should be verified with the company. An individual should not invest in the securities of NuGN) and other investor resources can information contained in this advertisement. Information about many publicity traded companies, including NuGene International, Inc. (NUGN) and other investor resources can information contained in this advertisement, information about many publicly traded companies, including Nulsene International, inc. (NULSN) and other investor resources can be found at the Securities and Exchange Commission's website at www.sec.gov. Investing in securities is highly speculative and carries significant risk. It is recommended that any investment in any security should be made only after consulting with your investment advisor and only after reviewing all publicly available information, including the financial statements of the company. This mailing piece is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy securities, nor should it be construed as the provision of any investment-related advice or services tallored to any particular individual's financial situation or investment tobjective(s). MicroCap MarketPlace is a bona fide publication of general and regular circulation offering impersonalized investment to readers and/or prospective readers and is not an investment adviser or broker/dealer registered with either the U.S. Securities and Exchange Commission (SEC) or with any state securities regulatory authority. MicroCap MarketPlace is neither licensed on or qualified to provide financial advice. As such, it relies upon the "publisher's exclusion" as provided under Section 202(a)(11) of the Investment Advisers Act. neither liberised for qualified to provide that the activity of the second of 1940 and corresponding state securities laws. Investing in companies like NuGene international, Inc. (NUGN) carries a high degree of risk. Do not invest in this company unless you can afford to possibly lose your entire investment. Casson Media Group, Inc. (CMG), an affiliated company of MicroCap MarketPlace has received nine thousand dollars in cash compensation from Result Corporation, a third party shareholder of NUGN to assist in the writing of this Advertisement, and anticipates receiving potential future oblias in Cash Competition, a dark party as a sensor of the Competition and advertising revenues, the amount of which is not known and cannot be predicted at this time. Result Corporation, besides competition from funding from the predicted at this time. Result Corporation, besides competition from funding from the competition of the (NUGN). Result Corporation fully intends to sell their shares without notice into this Advertisement/market awareness campaign, including selling into increased volume and share price that may result from this Advertisement/market awareness campaign. Rosalt Corporation may also purchase shares without notice at any time before, during or after this Advertisement/market awareness campaign. Non-affiliate shareholders acted as advisors to Result Corporation in this Advertisement and market awareness campaign. In cluding providing outside research, materials, and information to outside written materials as part of this market awareness campaign. It is believed that all outside research, materials and information used to compile this Advertisement, are accurate and reliable. However, each person should perform their own due diligence and consult with advisors of their choice in making any investment decision. MicroCap MarketPlace presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. Staff members of MicroCap MarketPlace and its affiliates do not hold positions in investments mentioned herein. Past performance does not guarantee future results. Additionally, it includes forward-looking statements affiliates do not within the meaning of Section 27A of the Securities and internation 21E of the Securities Exchange Act of 1934, including statements regarding expected growth of the featured company. Any statements that express or involve discussions with respect to predictions, expectation, beliefs, plans, projections, objectives, goods, assumptions or future events or performance may be forward-looking statements. The forward-looking statements are made that involve a significant number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. To the fullest extent of that involve a significant number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided herein, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).



Join Mega-Weathly Business-Mogul Kathy Ireland in NUGN as She Impacts the \$195 Billion Anti-Aging Market

Stem Cell Breakthrough Could Send NUGN Shares Soaring!